Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
| 15.52 | |
| 15.63 | |
| - | |
| 15.82 | |
| 15.185 | |
| 8.08-20.04 | |
| 325 M | |
| 21 179 K | |
| 72 881 K | |
| -1.47 | |
| 0.603 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Enanta Pharmaceuticals (ENTA) shares rallied 13.8% in the last trading session to close at $12.04. This move can be attributable to notable volume with a higher number of shares being traded than in a...
Expansion into Immunology with New Discovery Program of Oral KIT Inhibitors Addressing High Unmet Need in Chronic Spontaneous Urticaria (CSU); Development Candidate Selection Targeted for 2024 Expect ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
